LDHAL6CP: A Potential Drug Target for Cancer and Inflammation

Target Name: LDHAL6CP

NCBI ID: G121498

LDHAL6CP

Other Name(s): LDH6C | Lactate dehydrogenase A like 6C, pseudogene | lactate dehydrogenase A like 6C, pseudogene

LDHAL6CP: A Potential Drug Target for Cancer and Inflammation

The protein known as LDHAL6CP (LDH6C) is a member of the light chain protein family, which is a subgroup of the nucleoprotein complex that plays a crucial role in the immune response and inflammation. LDHAL6CP is a 21- kDa protein that is expressed in a variety of tissues and cells, including muscle, heart, brain, and cancer cells.

The LDHAL6CP protein has been identified as a potential drug target due to its involvement in a variety of cellular processes that are associated with cancer progression. In addition, its role in inflammation has also been implicated in the development of several diseases, including cardiovascular disease and autoimmune disorders.

LDHAL6CP functions as a negative regulator of the T-cell receptor (TCR), which is a critical component of the immune system that plays a crucial role in recognizing and responding to foreign antigens. LDHAL6CP helps to maintain the stability of the TCR, ensuring that it is able to properly recognize and respond to antigens.

One of the key functions of LDHAL6CP is its role in the regulation of the cytoskeleton. LDHAL6CP is a component of the cytoskeleton and helps to maintain the integrity of the cell's cytoplasm. It does this by interacting with several different cytoskeleton components, including the microtubules of the spindle (centrosome) and the microtubules of the centrioles (centrioles).

In addition to its role in cytoskeleton regulation, LDHAL6CP is also involved in the regulation of cell adhesion. LDHAL6CP is a component of the adhesion molecules, which are a family of transmembrane proteins that help to maintain the integrity of tissues and organs.

LDHAL6CP is also involved in several signaling pathways that are associated with cancer progression. For example, LDHAL6CP has been shown to be involved in the regulation of the angiogenic switch, which is the process by which cancer cells develop the ability to migrate and invade other tissues.

LDHAL6CP has also been implicated in the development of several diseases, including cardiovascular disease and autoimmune disorders. For example, studies have shown that LDHAL6CP is expressed in the hearts of mice and that its levels are increased in hearts that have been treated with several different therapies , including chemotherapy and radiation therapy.

In addition to its potential clinical applications, LDHAL6CP also has significant potential as a drug target. The development of small molecules that can specifically modulate LDHAL6CP activity has the potential to lead to new treatments for a variety of diseases.

Conclusion

In conclusion, LDHAL6CP is a protein that plays a critical role in several cellular processes that are associated with cancer progression and disease development. Its role in cytoskeleton regulation, cell adhesion, and signaling pathways makes it an attractive target for small molecules. Further research is needed to fully understand the mechanisms of LDHAL6CP's role in disease and to develop new treatments based on its properties.

Protein Name: Lactate Dehydrogenase A Like 6C, Pseudogene

The "LDHAL6CP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LDHAL6CP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets